New approaches to adherence issues when dosing oral aminosalicylates in ulcerative colitis

American Journal of Health-System Pharmacy

Volumn 66, Issue 5, 2009, Pages 451-457

  Tindall, William N ^a  

^a WRIGHT STATE UNIVERSITY   (United States)

Author keywords

Aminosalicylates; Colitis; Compliance; Dosage schedules; Half life; Patients; Toxicity

Indexed keywords

AZULFIDINE EN; BALSALAZIDE; MESALAZINE; OLSALAZINE; PLACEBO; SALAZOSULFAPYRIDINE; UNCLASSIFIED DRUG; AMINOSALICYLIC ACID DERIVATIVE;

ABDOMINAL DISCOMFORT; BLOATING; COLON FLORA; COLORECTAL CANCER; DOSAGE SCHEDULE COMPARISON; DRUG DELIVERY SYSTEM; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG PELLET; DRUG RELEASE; DRUG RETENTION; ECONOMIC ASPECT; HUMAN; PATIENT COMPLIANCE; PILL; PRIORITY JOURNAL; REMISSION; REVIEW; TABLET; TREATMENT OUTCOME; ULCERATIVE COLITIS; DOSE RESPONSE; DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; RECURRENT DISEASE;

ADMINISTRATION, ORAL; AMINOSALICYLIC ACIDS; COLITIS, ULCERATIVE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; HUMANS; MEDICATION ADHERENCE; RECURRENCE; TREATMENT OUTCOME;

EID: 63049092081     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp070442     Document Type: Review

References (71)

1. Loftus EV Jr. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology. 2004; 126:1504-17.
2. Han SW, McColl E, Barton JR et al. Predictors of quality of life in ulcerative colitis: the importance of symptoms and illness representations. Inflamm Bowel Dis. 2005; 11:24-34.
3. Carter MJ, Lobo AJ, Travis SP. Guidelines for the management of inflammatory bowel disease in adults. Gut. 2004;53(suppl 5):V1-16.
4. Kornbluth A, Sachar DB, Practice Parameters Committee of the American College of Gastroenterology. Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. 2004; 99:1371-85.
5. Lichtenstein GR, Kamm MA, Panaccione R et al. The effect of prolonged therapy with MMX mesalamine in patients with acute, mild-to-moderate ulcerative colitis. Am J Gastroenterol. 2007; 102:s2. Abstract 953.
6. Nielsen OH. Sulfasalazine intolerance. A retrospective survey of the reasons for discontinuing treatment with sulfasalazine in patients with chronic inflammatory bowel disease. Scand J Gastroenterol. 1982; 17:389-93.
7. Ghosh S, Shand A, Ferguson A. Ulcerative colitis. Br Med J. 2000; 320:1119-23.
8. Ishaq S, Green JR. Tolerability of aminosalicylates in inflammatory bowel disease. BioDrugs. 2001; 15:339-49.
9. Sutherland L, MacDonald JK. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2006; 2:CD000544.
10. Sutherland L, MacDonald JK. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2006; 2:CD000543.
11. Gionchetti P, Ardizzone S, Benvenuti ME et al. A new mesalazine gel enema in the treatment of left-sided ulcerative colitis: a randomized controlled multicentre trial. Aliment Pharmacol Ther. 1999; 13:381-8.
12. Kane S, De Vos M, Riley S et al. Compliance issues in inflammatory bowel disease. Rev Gastroenterol Disord. 2005;5:101-6.
13. Kane SV, Cohen RD, Aikens JE et al. Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis. Am J Gastroenterol. 2001; 96:2929-33.
14. Kane SV, Aikens JE, Hanauer SB. Medication regimens are associated with non-adherence in quiescent ulcerative colitis. Am J Gastroenterol. 2002; 97:S253. Abstract 770.
15. Kane S, Huo D, Aikens J et al. Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. Am J Med. 2003; 114:39-43.
16. Kane SV, Bjorkman DJ. The efficacy of oral 5-ASAs in the treatment of active ulcerative colitis: a systematic review. Rev Gastroenterol Disord. 2003; 3:210-8.
17. Dew MJ, Hughes PJ, Lee MG et al. An oral preparation to release drugs in the human colon. Br J Clin Pharmacol. 1982;14:405-8.
18. Hardy JG, Healey JN, Reynolds JR. Evaluation of an enteric-coated delayed-release 5-aminosalicylic acid tablet in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 1987; 1:273-80.
19. Myers B, Evans DN, Rhodes J et al. Metabolism and urinary excretion of 5-amino salicylic acid in healthy volunteers when given intravenously or released for absorption at different sites in the gastrointestinal tract. Gut. 1987; 28:196-200.
20. Rasmussen SN, Bondesen S, Hvidberg EF et al. 5-Aminosalicylic acid in a slow-release preparation: bioavailability, plasma level, and excretion in humans. Gastroenterology. 1982; 83:1062-70.
21. Staerk LL, Stokholm M, Bukhave K et al. Disposition of 5-aminosalicylic acid by olsalazine and three mesalazine preparations in patients with ulcerative colitis: comparison of intraluminal colonic concentrations, serum values, and urinary excretion. Gut. 1990;31:1271-6.
22. Willoughby CP, Aronson JK, Agback H et al. Distribution and metabolism in healthy volunteers of disodium azodi-salicylate, a potential therapeutic agent for ulcerative colitis. Gut. 1982; 23:1081-7.
23. Chan RP, Pope DJ, Gilbert AP et al. Studies of two novel sulfasalazine analogs, ipsalazide and balsalazide. Dig Dis Sci. 1983;28:609-15.
24. Fleig WE, Laudage G, Sommer H et al. Prospective, randomized, double-blind comparison of benzalazine and sulfasalazine in the treatment of active ulcerative colitis. Digestion. 1988;40:173-80.
25. Kane SV, Hanauer SB. National adherence rates with IBD therapy: po vs pr. Am J Gastroenterol. 2001; 96:S296. Abstract 938.
26. Kane SV. Systematic review: adherence issues in the treatment of ulcerative colitis. Aliment Pharmacol Ther. 2006; 23:577-85.
27. Eaden JA, Abrams KR, Mayberry JE. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut. 2001;48:526-35.
28. Karlén P, Löfberg R, Brostrom O et al. Increased risk of cancer in ulcerative colitis: a population-based cohort study. Am J Gastroenterol. 1999;94:1047-52.
29. Robinson M, Hanauer S, Hoop R et al. Mesalamine capsules enhance the quality of life for patients with ulcerative colitis. Aliment Pharmacol Ther. 1994; 8:27-34.
30. Saibeni S, Cortinovis I, Beretta L et al. Gender and disease activity influence health-related quality of life in inflammatory bowel diseases. Hepatogastroenterology. 2005;52:509-15.
31. Bangalore S, Shahane A, Parkar S et al. Compliance and fixed-dose combination therapy. Curr Hypertens Rep. 2007; 9:184-9.
32. Bezie Y, Molina M, Hernandez N et al. Therapeutic compliance: a prospective analysis of various factors involved in the adherence rate in type 2 diabetes. Diabetes Metab. 2006;32:611-6.
33. Kaiser HB. Compliance and noncompliance in asthma. Allergy Asthma Proc. 2007; 28:514-6.
34. Grijalva CG, Chung CP, Arbogast PG et al. Assessment of adherence to and persistence on disease-modifying antirheumatic drugs (DMARDs) in patients with rheumatoid arthritis. Med Care. 2007;45(10, suppl 2):S66-76.
35. Bagchi AD, Esposito D, Kim M et al. Utilization of, and adherence to, drug therapy among Medicaid beneficiaries with congestive heart failure. Clin Ther.2007;29:1771-83.
36. Gehi AK, Ali S, Na B et al. Self-reported medication adherence and cardiovascular events in patients with stable coronary heart disease: the Heart and Soul Study. Arch Intern Med. 2007; 167:1798-803.
37. Miller NH. Compliance with treatment regimens in chronic asymptomatic diseases. Am J Med. 1997; 102:43-9.
38. Farup P, Hinterleitner T, Lukas M et al. Mesalazine 4 g daily given as prolonged-release granules twice daily and four times daily is at least as effective as prolonged-release tablets four times daily in patients with ulcerative colitis. Inflamm Bowel Dis. 2001;7:237-42.
39. Sewitch MJ, Abrahamowicz M, Barkun A et al. Patient nonadherence to medication in inflammatory bowel disease. Am J Gastroenterol. 2003; 98:1535-44.
40. Shale MJ, Riley SA. Studies of compliance with delayed-release mesalazine therapy in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2003;18:191-8.
41. Loftus EV Jr. A practical perspective on ulcerative colitis: patients' needs from aminosalicylate therapies. Inflamm Bowel Dis. 2006; 12:1107-13.
42. Thomsen RW. The lesser known effects of statins: benefits on infectious outcomes may be explained by "healthy user" effect. BMJ. 2006;333:980-1.
43. Bernklev T, Jahnsen J, Aadland E et al. Health-related quality of life in patients with inflammatory bowel disease five years after the initial diagnosis. Scand J Gastroenterol. 2004; 39:365-73.
44. Casellas F, Arenas JI, Baudet JS et al. Impairment of health-related quality of life in patients with inflammatory bowel disease: a Spanish multicenter study. In flamm Bowel Dis. 2005; 11:488-96.
45. Janke KH, Raible A, Bauer M et al. Questions on life satisfaction (FLZM) in inflammatory bowel disease. Int J Colorectal Dis. 2004; 19:343-53.
46. Janke KH, Klump B, Gregor M et al. Determinants of life satisfaction in inflammatory bowel disease. Inflamm Bowel Dis. 2005; 11:272-86.
47. Rutter M, Saunders B, Wilkinson K et al. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology. 2004; 126:451-9.
48. Velayos FS, Terdiman JP, Walsh JM. Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies. Am J Gastroenterol. 2005;100:1345-53.
49. Eaden J, Abrams K, Ekbom A et al. Colorectal cancer prevention in ulcerative colitis: a case-control study. Aliment Pharmacol Ther. 2000; 14:145-53.
50. Bassi A, Dodd S, Williamson P et al. Cost of illness of inflammatory bowel disease in the UK: a single centre retrospective study. Gut. 2004; 53:1471-8.
51. Odes S, Vardi H, Friger M et al. Cost analysis and cost determinants in a European inflammatory bowel disease inception cohort with 10 years of follow-up evaluation. Gastroenterology. 2006;131:719-28.
52. Stark R, König HH, Leidl R. Costs of inflammatory bowel disease in Germany. Pharmacoeconomics. 2006; 24:797-814.
53. Blomqvist P, Ekbom A. Inflammatory bowel diseases: health care and costs in Sweden in 1994. Scand J Gastroenterol. 1997; 32:1134-9.
54. Hay AR, Hay JW. Inflammatory bowel disease: medical cost algorithms. J Clin Gastroenterol. 1992; 14:318-27.
55. Longobardi T, Jacobs P, Wu L et al. Work losses related to inflammatory bowel disease in Canada: results from a National Population Health Survey. Am J Gastroenterol. 2003; 98:844-9.
56. Mackowiak JI. A two-stage decision analysis to assess the cost of 5-aminosalicylic acid failure and the economics of balsalazide versus mesalamine in the treatment of ulcerative colitis. Manag Care Interface. 2006; 19:39-46,56.
57. Piodi LP, Ulivieri FM, Cermesoni L et al. Long-term intermittent treatment with low-dose 5-aminosalicylic enemas is efficacious for remission maintenance in ulcerative colitis. Scand J Gastroenterol. 2004;39:154-7.
58. Borrill J, Bhatt A, Bodger K. A pharmacoeconomic evaluation of high dose oral mesalazine for moderately active ulcerative colitis: a decision analytic model. Colorectal Dis. 2007; 8(suppl 2):44.
59. Kane S, Huo D, Magnanti K. A pilot feasibility study of once daily versus conventional dosing mesalamine for maintenance of ulcerative colitis. Clin Gastroenterol Hepatol. 2003; 1:170-3.
60. Hanauer S, Sandborn W, Kornbluth A et al. Delayed-release oral mesalamine 4.8g/day (800mg tablet) versus 2.4g/day (400mg tablet) for the treatment of moderately active ulcerative colitis: combined analysis of two randomised, double-blind, controlled trials. Gastroenterology. 2005; 128:A-74-5. Abstract 492.
61. Hanauer S, Sandborn W, Kornbluth A et al. Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial. Am J Gastroenterol. 2005; 100:2478-85.
62. Brunner M, Greinwald R, Kletter K et al. Gastrointestinal transit and release of 5-aminosalicylic acid from 153Sm-labelled mesalazine pellets vs. tablets in male healthy volunteers. Alim Pharmacol Ther. 2003; 17:1163-9.
63. Wilding I, Behrens C, Tardif S et al. Combined scintigraphic and pharmacokinetic investigation of enteric-coated mesalazine micropellets in healthy subjects. Alim Pharmacol Ther. 2003; 17:1153-62.
64. Raedler A, Behrens C, Bias R Mesalazine (5-aminosalicylic acid) micropellets show similar efficacy and tolerability to mesalazine tablets in patients with ulcerative colitis-results from a randomized-controlled trial. Alim Pharmacol Ther. 2004;20:1353-63.
65. Prantera C, Viscido A, Biancone L et al. A new oral delivery system for 5-ASA: preliminary clinical findings for MMx. Inflamm Bowel Dis. 2005; 11:421-7.
66. Lichtenstein GR, Kamm MA, Boddu P et al. Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis. Clin Gastroenterol Hepatol. 2007; 5:95-102.
67. Kamm MA, Sandborn WJ, Gassull M et al. Once-daily high concentration MMX mesalamine in active ulcerative colitis. Gastroenterology. 2007; 132:66-75.
68. Sutherland LR, Martin F, Greer S et al. 5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis. Gastroenterology. 1987; 92:1894-8.
69. Sandborn WJ, Kamm MA, Lichtenstein GR et al. Combined data from two pivotal, randomized, placebo-controlled, phase III studies show that SPD476, a novel mesalamine formulation given once or twice daily, is effective for the induction of remission of mild-to-moderate ulcerative colitis. Gastroenterology. 2007; 130(4, suppl 2):A-119. Abstract 813.
70. Sandborn WJ, Kamm MA, Lichtenstein GR et al. Multi Matrix System mesalazine for the induction of remission in patients with mild-to-moderate ulcerative colitis: a combined analysis of two randomized, double-blind, placebo-controlled trials. Alim Pharmacol Ther. 2007; 26:205-15.
71. Lichtenstein GR, Kamm MA, Sandborn WJ et al. MMX mesalamine for the induction of remission of mild-to-moderately active ulcerative colitis: efficacy and tolerability in patient sub-populations. Aliment Pharmacol Therapy. 2008;27:1094-1102.